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Abstract
Introduction Endoscopic transmural drainage (ED) or
percutaneous drainage (PD) has mostly replaced surgery
for the initial management of patients with symptomatic
pancreatic fluid collections (PFCs). This study aimed to
compare outcomes for patients undergoing ED or PD of
symptomatic PFCs.
Methods Between January 2000 and December 2013, all
patients who required PD or ED of a PFC were included.
Rates of treatment success, length of hospital stay, adverse
events, re-interventions and length of follow-up were
recorded retrospectively in all cases.
Results In total, 164 patients were included in the study;
109 patients underwent ED; and 55 had PD alone. During
the 14-year study period, the incidence of ED increased
and PD fell. In the 109 patients who were managed by ED,
treatment success was considerably higher than in those
managed by PD (70 vs. 31 %). Rates of procedural adverse
events were higher in the ED cohort compared to the PD
group (10 vs. 1 %), but patients managed by ED required
fewer interventions (median of 1.8 vs. 3.3) had lower rates
of residual collections (21 vs. 67 %) and need for surgical
intervention (4 vs. 11 %). In the ED group, treatment
success was similar for walled-off pancreatic necrosis
(WOPN) and pseudocysts (67 vs. 72 %, P = 0.77). There
were no procedure-related deaths.
Conclusion Compared with PD, ED of symptomatic
PFCs was associated with higher rates of treatment success,
lower rates of re-intervention, including surgery and
shorter lengths of hospital stay. Outcomes in WOPN were
comparable to those in patients with pseudocysts.
Keywords Acute pancreatitis  Chronic pancreatitis 
Pseudocyst  Walled-off pancreatic necrosis  Endoscopic
ultrasound  Endoscopic drainage
Pancreatic fluid collections (PFCs) are collections of pan-
creatic fluid or debris that are encased in a wall of granu-
lation tissue. They occur following acute pancreatitis,
pancreatic surgery, abdominal trauma or chronic obstruc-
tion of the pancreatic duct, e.g. in chronic pancreatitis or
pancreatic malignancy [1–3]. PFCs are estimated to occur
in 5–16 % [4] of patients with acute pancreatitis and up to
40 % of patients with chronic pancreatitis [5].
While most asymptomatic inflammatory pancreatic
collections, especially if small (e.g.\4 cm), will resolve
spontaneously and can be managed conservatively [6],
once a PFC increases to 6 cm or becomes symptomatic
(e.g. infection, abdominal pain, biliary or gastric outlet
obstruction), rates of spontaneous resolution are much
lower and drainage is recommended [7–11]. The manage-
ment of asymptomatic PFCs larger than 6 cm remains
debated, but conservative management is often advocated
given the potential for procedure-associated morbidity in
an asymptomatic patient [10].
PFCs may be drained surgically, by radiologically gui-
ded percutaneous drainage (PD), or endoscopically, usually
by endoscopic transmural drainage (ED). Historically,
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surgery was considered the standard initial management for
PFCs, but given its invasive nature, morbidity, longer
length of hospital stay and increased associated costs, there
has been a growing interest in less invasive approaches for
the management of PFCs, such as PD or ED [2, 3, 12–15].
The first reports of the endoscopic creation of a fistulous
tract between a PFC and the gastrointestinal tract were
published in the 1980s [16–18]. Since these early
descriptions, the technique has evolved and now routinely
combines endoscopic ultrasound (EUS) enabling the drai-
nage of non-bulging collections and reducing associated
adverse events [2, 3, 19–23.]
Previous studies have compared surgical drainage with
PD [14, 24–27] and ED [13]. One group compared all three
approaches, but in this study, only a few patients under-
went PD, so the final analysis focused on outcomes for
surgical and ED [28]. A subsequent study did compare
outcomes for PD and ED, but focused on outcomes in
pseudocysts [29]. Increasingly, necrotic PFC are being
managed by minimally invasive approaches given the
morbidity associated with open surgical interventions [2, 3,
30], but there remains a lack of information about the
optimal minimally invasive drainage method in different
PFCs.
Study aim
The aim of this study is to compare the outcomes of
endoscopic or percutaneous drainage in patients with
symptomatic PFC.
Methods
Setting
A large regional hepatopancreaticobiliary centre based
across two tertiary care hospitals: University College
London Hospital NHS Foundation Trust (UCLH) and the
Royal Free Hospital NHS Foundation Trust (RFH).
Design
This is a retrospective cohort study.
Ethical approval
The study was registered as a clinical audit at University
College London NHS Foundation Trust and the Royal Free
Hospital NHS Foundations Trust and conducted in accor-
dance with the Helsinki Declaration [31].
Definitions
Pancreatic fluid collection (PFC)
PFC in this study was defined as measuring[4 cm on CT/
MRCP and located within or adjacent to the pancreas, in
patients with a documented history of acute or chronic
pancreatitis, pancreatic surgery or malignancy.
Types of PFCs
PFCs were defined in accordance with the revised Atlanta
criteria: [1]
• Pseudocyst collection of fluid encapsulated within a
well-defined inflammatory wall containing no solid
components or necrosis. Present for[4 weeks.
• Walled-off pancreatic necrosis (WOPN) mature,
encapsulated collection of pancreatic ± peripancreatic
necrosis that has a well-defined inflammatory wall.
Present for[4 weeks.
Treatment success
Treatment success was defined as the successful insertion
of a stent or drain with complete resolution or a decrease in
the size of the PFC to B2 cm on follow-up CT.
Residual PFC
A residual collection was defined as the presence of a PFC
([2 cm), which did not resolve on imaging following
percutaneous or endoscopic drainage.
Recurrent PFC
Recurrence was defined as the presence of a PFC on
imaging after resolution of the initial collection.
Re-intervention
Re-intervention was defined as the need for repeat drainage
or surgery owing to persistent symptoms in association
with a residual PFC on follow-up imaging.
Length of stay
Length of hospital stay was defined as the time to discharge
from the day of the first percutaneous drainage (percuta-
neous management group) or first endoscopic transmural
drainage (endoscopic management group).
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Infected collection
An infected PFC was diagnosed based on fever, raised
inflammatory markers, radiological findings (e.g. gas bub-
bles within the PFC) or positive culture from the PFC
following aspiration.
Procedure: EUS-guided transmural drainage
Prior to EUS, cross-sectional imaging (computed tomog-
raphy (CT) or magnetic resonance imaging (MRI)/mag-
netic resonance cholangiopancreatography (MRCP)) was
performed within 4 weeks, to determine the size and
location of the cyst, as well as to evaluate for interposed
vascular structures or evidence of pancreatic duct disrup-
tion necessitating a pancreatic stent.
The procedures were performed under conscious seda-
tion or general anaesthesia, a linear array echoendoscope
(Pentax Medical, UK or Olympus, UK) was used to ensure
the distance between the gastric and/or duodenal wall, the
PFC was\1 cm, and there were no interposed blood ves-
sels on Doppler.
In the majority of cases, the PFC was accessed from the
stomach using a cystotome (Cook Medical, Limerick, Ire-
land). In other cases, access was obtained using a needle
knife or 19-gauge fine needle aspiration needle (ECHO-19;
Cook Medical or Expect; Boston Scientific, Hemel
Hempstead, UK). Entry was confirmed by aspiration of
cyst contents, after which two 0.035-inch guidewires were
then advanced into the PFC and allowed to coil within the
cyst under fluoroscopic guidance, which was used in all
cases. The tract was then dilated with a controlled radial
expansion (CRE) wire-guided balloon (Boston Scientific)
or Soehendra biliary dilator. Usually, two double-pigtail
stents (7F) of various lengths were then inserted into the
fistulotomy using a Teflon pusher catheter (Cook Medical).
Cyst fluid was obtained and sent for Gram stain, culture
and fluid amylase levels as clinically indicated.
Patients were discharged when clinically stable (aim
within 24 h) and prescribed a short course of oral antibi-
otics for up to 5 days. They were then followed up in clinic
3–6 monthly as necessary. Transmural stents were gener-
ally removed 9–12 months after insertion, as long as the
PFC had resolved on cross-sectional imaging. If patients
remained symptomatic, and the PFC persisted or recurred,
additional drainage was performed following discussion at
the hepatopancreaticobiliary (HPB) multidisciplinary
meeting.
Procedure: percutaneous drainage
Percutaneous drainage was performed by a HPB radiologist
under CT, ultrasound (US) and/or fluoroscopic guidance.
The PFC was identified, and a suitable access route
selected, which avoided the spleen, interposed bowel and
blood vessels. The skin was marked and local anaesthesia
administered (subcutaneous injection of 1 % lidocaine).
The PFC was then punctured under imaging guidance with
an 18-gauge single-wall needle (Cook Medical).
A Seldinger technique was then used to sequentially dilate
the tract over a 0.035-inch, non-hydrophilic guidewire
(Cook Medical). A multiple-side holed 8F–12F (Flexima
APDL; Boston Scientific) locking catheter was then placed
and secured to the skin with 2-0 nylon suture. Drain output
was monitored daily, and decisions about upsizing,
replacing or removing the drain were made based on sub-
sequent imaging and the clinical progress of the patient.
Inclusion criteria
Patients with a PFC requiring percutaneous or endoscopic
transmural drainage between 1 January 2000 and 31
December 2013.
Exclusion criteria
• Patients\18 years.
• PFC\4 cm in size or managed conservatively.
• Patients who were managed by surgery (n = 13), EUS-
guided fine needle aspiration (EUS-FNA) (n = 7)
or endoscopic retrograde cholangiopancreatography
(ERCP) and transpapillary drainage (n = 2) alone.
Data recorded
Cases were identified primarily from records of the benign
HPB multidisciplinary team meetings, which are held
weekly. In addition, the Pathology (CoPath histology
database, Sunquest, Tucson AZ, USA), Endoscopy (GI
reporting tool, Unisoft medical systems, UK) and Imaging
(PACS: picture archiving and communication system, GE
Healthcare, USA) databases were searched using the fol-
lowing terms, pseudocyst, walled-off necrosis, pancreatic
fluid collection.
The electronic medical records of the included patients
were reviewed, and information was recorded in an elec-
tronic spreadsheet. Data collected included demographic
information (age, sex, hospital number), initial symptoms,
history of acute or chronic pancreatitis or malignancy,
family history of pancreatic cancer or relevant clinical
syndrome and serum amylase on admission, where avail-
able. Cross-sectional imaging (CT and/or MR/MRCP)
features that were recorded included size (maximal
dimension), location, number of cystic lesions, presence of
a necrosis, features of acute or chronic pancreatitis,
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dilatation of the pancreatic duct or biliary tree, communi-
cation of the cystic lesion with the main pancreatic duct,
ascites, pleural effusion or the presence of features of
portal hypertension. For patients undergoing endoscopy
(ERCP or EUS), imaging features were recorded in addi-
tion to details of the drainage technique and cytology,
histology or culture results where available. For patients
ultimately referred for surgery, date of the operation, type
of resection and final histology were recorded. Length of
follow-up was calculated from first procedure to last clinic
appointment attended, or date of clinic discharge, or death.
Statistical analyses
Statistical Package for Social Sciences for Windows, ver-
sion 18.0 (SPSS Inc., Chicago, IL, USA), was used to
perform all statistical analyses. Associations between
malignancy and various clinical and radiographic charac-
teristics were evaluated using a two-sample t test for con-
tinuous variables and a Chi-squared test for categorical
variables.
Results
Between January 2000 and December 2013, 270 patients
with a PFC were evaluated at UCLH and the RFH. In total,
84 patients were managed conservatively and 13 by sur-
gery alone and were excluded from the study (Fig. 1). Two
patients had ERCP and transpapillary drainage and seven
EUS-guided fine needle aspiration (EUS-FNA) to dryness
alone; these cases were also excluded. The 7 patients
having EUS-FNA alone were initially referred for consid-
eration of ED, but at the time of the procedure, ED was not
performed because of small cyst size (n = 2) or phlegmon
containing largely solid material (n = 5).
Of the 164 patients included in the study, 109 patients
underwent ED and 55 patients had PD alone (Fig. 1).
During the study period, the overall number of patients
undergoing drainage of their PFC increased annually, and
the number of patients managed by PD alone decreased in
favour of ED for both first-line and definitive management
of a PFC (Fig. 2).
Diagnostic investigations
Clinical features and laboratory tests
Patient demographics are outlined in Table 1. The median
age of patients undergoing ED was 55 years (range
22–84 years) compared to 50 years (range 20–87 years)
for those receiving PD alone. Both groups had more male
than female patients; 55 % (60) in the ED group and 67 %
[37] in the PD group. The most common aetiologies of
pancreatitis in both groups were gallstones and alcohol. In
the ED group, more patients had gallstone pancreatitis (45
vs. 26 %; P = 0.01), and in the PD group, slightly more
patients had alcohol-related pancreatitis (24 vs. 19 %). The
cause of pancreatitis remained indeterminate in 25 % of the
ED group and 38 % of those who underwent PD alone.
Cross-sectional imaging
Abdominal CT was used to confirm the presence of a PFC
in all patients. Both CT and MRCP/MRI were performed in
46 % (76/164) of patients. The median size of the PFC
managed by ED or PD was similar; 103 versus 102 mm,
respectively. In both groups, approximately two-thirds of
the collections were located within or adjacent to the body
or tail of the pancreas. In total, 32 % of those undergoing
ED and 42 % of those receiving PD had evidence of
chronic pancreatitis on cross-sectional imaging immedi-
ately prior to drainage. The ED group contained fewer
patients with necrotising pancreatitis (35 vs. 55 %). Evi-
dence of portal hypertension on imaging was common in
both groups, 49 % in the ED group and 42 % in the PD
group (Table 2).
Post-inflammatory 
pancreatic collections 
2000-2013 (n=270)
Percutanous drainage 
(n=55)
WOPN (n=30) Pseudocyst (n=25)
Endoscopic Drainage 
(n=109)
WOPN (n=38)
Pseudocyst (n=71)
EXCLUDED: 
- Conservative management (n=84)
- Surgical management alone (n=13)
- ERCP + TPD (n=2)
- EUS-FNA (n=7)
Fig. 1 Flow chart demonstrating patient selection and proportion of
patients with pseudocysts and WOPN in each cohort. WOPN walled-
off pancreatic necrosis, ERCP ? TPD endoscopic retrograde cholan-
giopancreatography ? transpapillary drainage, EUS-FNA endoscopic
ultrasound and fine needle aspiration
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Management and outcomes
Almost all drains were placed more than 4 weeks after the
onset of pancreatitis, with the exception of a few patients
with an infected PFC. In the PD group, the median time to
first drainage was 28 days (range 1–1444 days) compared
to 101 days (range 7–3183 days) in the ED group.
Of the ED procedures undertaken, 35 % were performed
in patients with WOPN (Table 3). Patients with WOPN
undergoing ED were older than the pseudocyst group (60
vs. 51 years), had larger collections (119 vs. 100 mm) and
had higher rates of portal hypertension (58 vs. 44 %). All
patients had symptoms attributable to their cyst, and the
most common indication for drainage was pain. Clinical
signs of infection were more frequent in the WOPN group
(76 vs. 37 %). When fluid was aspirated from a PFC for
culture, it was almost always positive (WOPN 96 vs.
pseudocysts 100 %). Most fluid aspirates had mixed
growth (WOPN 46 vs. pseudocysts 50 %), and patients
with WOPN were co-infected with methicillin-resistant
ED: Endoscopic Drainage, PD: Percutaneous Drainage
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ED PDFig. 2 Number of patients
undergoing drainage of a
pancreatic fluid collection
annually during the study period
Table 1 Characteristics of patients undergoing drainage of PFCs by management subtype
Endoscopic transmural drainage (n = 109) Percutaneous drainage (n = 55)
Median age of patient, years (range) 55 (22–84) 50 (20–87)
Sex
Male 55 % (60) 67 % (37)
Female 45 % (49) 33 % (18)
Aetiology
Gallstones 45 % (50) 26 % (14)
Alcohol 19 % (21) 24 % (13)
Post-ERCP or EUS 3 % (3) 6 % (3)
Hypercalcaemia 1 % (1) 2 % (1)
Alcohol ? gallstones 2 % (2) –
Hyperlipidaemia 1 % (1) –
Pancreatic/ampullary tumour 1 % (1) 2 % (1)
Post-pancreatic surgery 1 % (1) 2 % (1)
Tuberculosis – 2 % (1)
Incidental finding 2 % (2) –
Indeterminate 25 % (27) 38 % (21)
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Staphylococcus aureus (MRSA) and candida in 17 and
25 % of cases, respectively, compared to 5 and 9 % in
pseudocysts (Table 3).
Almost all (98 % (94/96)) ED were performed under
conscious sedation. The puncture was attempted through
the transgastric route in 98 % of the WOPN and 91 % of
pseudocysts. A 10F cystotome (Cook Medical) was used in
approximately two-thirds of cases. Stent insertion was
successful in 98 % of WOPN and 90 % of pseudocysts. A
median of two plastic double-pigtail stents (range 1–4)
were inserted. A fully covered self-expanding metal stent
(FCSEMS) (NAGI stent, Taewoong Medical, Gyeonggi-
do, Korea) was inserted in 4.6 % (5/109) of cases. Treat-
ment success was similar in both the WOPN and pseudo-
cyst groups (67 % (31/46) vs. 72 % (58/81), P = 0.77).
The median length of stay post-ED was 4 days and did not
differ between patients with pseudocysts and WOPN col-
lections, nor did the need for a further procedure (31 vs.
21 %, P = 0.11). Adverse events occurred in 10 % of
cases and were similar in both the WOPN and pseudocyst
groups. Adverse events included four episodes of stent
migration, three cases of pneumoperitoneum (one managed
conservatively with percutaneous drainage, while two
underwent laparotomy), two oesophageal perforations
which required laparotomy, two episodes of gastrointesti-
nal bleeding requiring blood transfusion and endoscopic or
radiological intervention, one pneumothorax which
required drainage and one aspiration pneumonia. No
patients died in the 30 days following the procedure.
In the 55 patients who were managed by PD, 18 % (10/
55) of the patients had the drain placed transgastrically, of
which 8 were internalised. Treatment success in the PD
group was considerably lower than those managed by ED
[31 % (30/97) vs. 70 % (89/127)]. During the median
follow-up period of 11 (0–131) months in the ED group
and 17 (1–150) months in the PD group, rates of failed
drain insertion and adverse events were lower in the PD
cohort compared to the ED group, 1 and 1 % versus 7 and
10 %, respectively. However, patients managed by PD
alone required more interventions (median of 3.3 vs. 1.8),
had higher rates of residual collections (67 vs. 21 %) and
ultimately a higher proportion required surgical manage-
ment (11 vs. 4 %) and had a longer hospital stay (median
42 vs. 4 days) (Table 4).
Patients managed by percutaneous drainage had an
external drain in situ for a median of 56 days (range
3–651 days). Cystenterostomy stents were left in situ
for a median of 277 days (range 20–1015 days) before
removal.
Discussion
Historically, PFCs have been managed by surgical drai-
nage. However, the associated morbidity and mortality of
pancreatic surgery have resulted in a growing interest in
alternative minimally invasive techniques. A recent ran-
domised study of 40 patients compared ED and surgical
drainage. ED was found to have comparable efficacy with
similar rates of adverse events but with a shorter hospital
stay [15]. In the present study, ED was associated with
higher rates of treatment success (70 vs. 31 %), a shorter
length of hospital stay and fewer subsequent interventions,
when compared to PD.
Table 2 Comparison of cross-sectional imaging features by management subtype
Endoscopic transmural drainage (n = 109) Percutaneous drainage (n = 55)
Median size of PFC ? range (mm) 103 (40–250) 102 (40–222)
Site
Head/neck 37 % (41) 36 % (20)
Body/tail 63 % (68) 64 % (35)
Acute pancreatitis 73 % (80) 76 % (42)
Chronic pancreatitis 32 % (35) 42 % (23)
Pancreatic necrosis 35 % (38) 55 % (30)
Pancreatic duct dilatation 39 % (43) 40 % (22)
Extrahepatic biliary dilation 35 % (38) 38 % (21)
Pseudoaneurysm 6 % [6 (2 haemorrhages)] 11 % [6 (4 haemorrhages)]
Ascites 11 % (12) 31 % (17)
Pleural effusion 16 % (17) 40 % (22)
Portal hypertension 49 % (53) 42 % (23)
Multiple pancreatic cysts 23 % (25) 35 % (19)
Lymph node enlargement 19 % (21) 13 % (7)
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Table 3 Comparison of clinical outcomes of endoscopic transmural drainage in walled-off pancreatic necrosis (WOPN) and pseudocysts
WOPN
Patients = 38
Procedures = 46
Pseudocyst
Patients = 71
Procedures = 81
Median age of patient, years (range) 60 (22–84) 51 (26–84)
Median maximal diameter—mm (range) 119 (67–200) 100 (40–250)
Portal hypertension % (n) 58 % (22) 44 % (31)
Reason for drainage % (n)
Pain 24 % (11) 43 % (35)
Increasing size ? pain 35 % (16) 32 % (26)
Infection 28 % (13) 11 % (9)
Gastric outlet obstruction 7 % (3) 6 % (5)
Unknown 7 % (3) 7 % (6)
Sedation % (n)
Conscious sedation 97 % (37) 98 % (58)
General anaesthesia 3 % (1) 2 % (1)
Unknown (8) (23)
Approach % (n)
Transgastric 98 % (42) 91 % (60)
Transduodenal 2 % (1) 9 % (6)
Unknown (3) (15)
Cystotome used 5 (n) 74 % (34) 67 % (54)
Number of stents inserted % (n)
Plastic
0 (Failed stent insertion/procedure abandoned) 2 % (1) 10 % (8)
1 9 % (4) 10 % (8)
2 70 % (32) 62 % (50)
3 4 % (2) 6 % (5)
4 2 % (1) 0 % (0)
Unknown 7 % (3) 10 % (8)
Fully covered self-expanding metal stents (FCSEMS) 7 % (3) 3 % (2)
Infection % (n)
Clinical signs of infection 76 % (29/38) 37 % (26/71)
Positive pancreatic fluid culture 96 % (23/24) 100 % (22/22)
Mixed growth 46 % (11) 50 % (11)
Streptococcus 0 % (0) 18 % (4)
Staphylococcus 17 % (4) 14 % (3)
E coli 13 % (3) 5 % (1)
Enterococcus 8 % (2) 5 % (1)
Other 16 % (4) 10 % (2)
Pancreatic fluid—co-infection
MRSA 17 % (4) 5 % (1)
Candida 25 % (6) 9 % (2)
Treatment success % (n) 67 % (31/46) 72 % (58/81)
Failed stent insertion/procedure abandoned 2 % (1/46) 10 % (8/81—2 cases required a further procedure)
Further procedure required 37 % (14/38) 24 % (17/71)
Adverse events % (n) 7 % (3) 12 % (10)
Stent migration 2 % (1) 4 % (3)
Haemorrhage—transfusion required 0 % (0) 3 % (2:1—acute, 1—delayed)
Pneumoperitoneum 2 % (1) 3 % (2)
Oesophageal perforation 0 % (0) 3 % (2)
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When compared to other case series, the rate of initial
technical success was similar, but overall treatment success
in this study (70 %) was lower than previously reported [3,
30]. However, it was comparable to series from centres
with a longer follow-up time allowing sufficient time to
diagnose recurrent or residual collections [32] and those
series which included a high proportion of complex cases
(e.g. WOPN and portal hypertension) [2, 3]. Other groups
have reported much lower rates of treatment success when
managing necrotic collections (25 vs. 93 %) [2], but in this
study, treatment success rates between WOPN and pseu-
docysts were comparable (67 vs 72 %). This may reflect
differences in technique such as the insertion of more than
two plastic stents or the use of FCSEMS in the manage-
ment of these collections.
Adverse events occurred in 10 % (n = 13) of the ED
cases, but all were successfully managed during the same
hospitalisation. Rates were comparable to those reported in
other ED studies and were similar or lower than those
following surgical drainage of a PFC [2, 3, 15, 23, 33, 34].
Other authors have also reported higher adverse events
when draining organised necrosis [2, 3]. This was not the
case in our series, where in fact adverse events were
slightly lower in the WOPN cohort compared to the
pseudocyst group (7 vs 12 %). The 30-day mortality fol-
lowing ED in this cohort was zero, compared to 0–7 % in
other series [2, 3, 15, 20, 23, 35–38].
Bacterial or fungal colonisation and systemic infection
are common sequelae of chronic PFC, particularly in the
presence of necrosis. As in this series, typically a range of
bacteria is isolated and fungal contamination is present in
up to a quarter of cases with WOPN [39]. EUS-guided
aspiration is therefore increasingly recommended to guide
antibiotic management [40]. Although not performed rou-
tinely in most centres, it appears to be a useful strategy for
guiding antibiotic and antifungal choice in the management
of infected PFCs.
In patients in this series managed by PD alone, rates of
treatment success were low and further procedures were
commonly required, similar to outcomes reported in other
PD series [14, 41–45]. PD also requires patients to
have a long-term external drain (median time in situ
of 56 days), which is commonly disliked by patients and
has been associated with the development of chronic pan-
creatic cutaneous fistulas [14, 41, 42, 44]. In our series,
although patients managed by PD had a longer length of
stay in hospital, rates of pancreatic cutaneous fistulas
were much lower (2 %) than previously reported, which
may be because a proportion (18 %) of the percutaneous
drains in our series were sited transgastrically, of which
most (80 %) were ultimately converted to an endoscopic
cystenterostomy.
One of the limitations of our study was that it was
conducted retrospectively. Outcomes for the PD group may
have been inferior due to the inclusion of patients with
more severe disease as evidenced by higher rates of
necrosis, ascites, pleural effusions, shorter time to first
drainage (28 vs. 101 days), and that four patients died due
to the complications of severe pancreatitis in this cohort.
Conclusions
ED is increasingly employed in the management of PFC.
This large series demonstrated superior rates of treatment
success, need for subsequent intervention and shorter
length of stay in hospital compared to patients managed by
PD alone. Outcomes and adverse events were similar for
WOPN and pseudocysts, supporting the use of ED in the
management of complex PFCs. Further high-quality
Table 3 continued
WOPN
Patients = 38
Procedures = 46
Pseudocyst
Patients = 71
Procedures = 81
Aspiration pneumonia 2 % (1) 0 % (0)
Pneumothorax 0 % (0) 1 % (1)
Residual PFC % (n) 22 % (10/46) 20 % (16/81)
Recurrent PFC % (n) 9 % (4/46) 5 % (4/81)
Number of drainage interventions required
Mean number of interventions (range) 2.3 (1–7) 1.5 (1–4)
Mean pre-ED (range) 0.9 (0–6) 0.3 (0–3)
Mean post-ED (range) 0.5 (0–3) 0.3 (0–3)
Surgical intervention ultimately required—% (n) 5 % (2) 3 % (2)
Length of stay: median number of days in hospital post-ED (range) 4 (0–36) 4 (0–63)
Surg Endosc
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studies are needed to fully define optimal pathways for the
use of ED in the management of PFC.
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